1. Home
  2. ACFN vs QTTB Comparison

ACFN vs QTTB Comparison

Compare ACFN & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACFN

Acorn Energy Inc.

HOLD

Current Price

$15.15

Market Cap

35.2M

ML Signal

HOLD

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$3.40

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACFN
QTTB
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.2M
40.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ACFN
QTTB
Price
$15.15
$3.40
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$7.33
AVG Volume (30 Days)
65.9K
392.4K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
473.47
N/A
EPS
2.64
N/A
Revenue
$12,630,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.72
N/A
Revenue Growth
30.11
N/A
52 Week Low
$12.42
$1.35
52 Week High
$33.00
$6.37

Technical Indicators

Market Signals
Indicator
ACFN
QTTB
Relative Strength Index (RSI) 47.62 62.07
Support Level $14.85 $3.08
Resistance Level $16.09 $3.29
Average True Range (ATR) 1.45 0.24
MACD 0.15 0.01
Stochastic Oscillator 48.99 95.83

Price Performance

Historical Comparison
ACFN
QTTB

About ACFN Acorn Energy Inc.

Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. It operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Share on Social Networks: